Marstacimab‑Hncq 150 mg/mL Suppliers & Bulk Manufacturers
Available Forms: injection (prefilled syringe)
Available Strengths: 150 mg/mL
Reference Brands: Hympavzi (USA)
Category: Plasma Products
Marstacimab-hncq is a human monoclonal IgG1 antibody that antagonizes the tissue factor pathway inhibitor (TFPI), thereby promoting thrombin generation and improving clot formation in patients with haemophilia A or B without inhibitors. It is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and adolescents (≥ 12 years) with haemophilia A without factor VIII inhibitors or haemophilia B without factor IX inhibitors.
Marstacimab‑Hncq — third party manufacturing & bulk supply
Marstacimab‑Hncq 150 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Indicative minimum order quantity
Marstacimab‑Hncq is supplied as injection (prefilled syringe) — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Marstacimab‑Hncq listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Marstacimab‑Hncq →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Marstacimab-hncq is used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and adolescents with hemophilia A or B who do not have inhibitors to coagulation factors VIII or IX.
Marstacimab-hncq is made from a recombinant human monoclonal antibody that targets and inhibits tissue factor pathway inhibitor (TFPI), thereby enhancing the generation of thrombin and improving blood clotting.
The trade name of Marstacimab-hncq is Amtuvemo.
Marstacimab-hncq is developed and manufactured by Pfizer Inc.
The generic name is Marstacimab-hncq.
The brand name is Amtuvemo.
Marstacimab-hncq (Amtuvemo) is manufactured by Pfizer Inc., in the United States.
Related Products
Emicizumab‑Kxwh
Strength:
30 mg/mL, 60 mg/0.4 mL, 105 mg/0.7 mL
Form: Injection
Reference Brands: Hemlibra (USA/EU)
View Details
Concizumab-Mtci
Strength:
60 mg/1.5 mL, 150 mg/1.5 mL, 300 mg/3 mL
Form: Prefilled autoinjector
Reference Brands: Alhemo (USA/EU)
View Details
Fresh Frozen Plasma (Ffp) Powder For Reconstitution Or Liquid
Strength:
available in 200-250 mL units
Form: liquid units or lyophilized (freeze-dried) powder
Reference Brands: No specific brands
View Details
Plasma Protein Fraction (Ppf) Powder
Strength:
50 mL, 250 mL, or 500 mL
Form: Lyophilized Powder or Liquid
Reference Brands: Plasmanate (US), Octaplas LG, Biotest Plasma (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
